These findings, together with the demonstration that inhibition of EGFR or the upstream inducers of EGFR signaling results in autophagic killing of type I, II, or atypical strains of T. gondii in various human and mouse cells (Muniz-Feliciano et al., 2013; Portillo et al., 2017; Lopez Corcino et al., 2019a), identified EGFR as a therapeutic target against toxoplasmosis. This evidence concerns the gene EGFR and toxoplasmosis.